According to the report, the Size of the North America Platelet Aggregation Devices Market is valued at USD 107.10 million in 2022 and is estimated to be growing at a CAGR of 19.92%, to reach USD 265.61 million by 2027 during the forecast period 2022 to 2027.
The increase in the elderly growing population as more than 16.9 percent of in the US is elderly and 18 percent in Canada respectively, rising burden of chronic illnesses such as cancer, diabetes, hemophilia, etc., and technical developments in platelet aggregometer are all contributing to the growth of the platelet aggregation devices market.
Heart issues, such as stroke and coronary heart disease, are becoming more common, resulting in a global burden of cardiac mortality, which has fueled the expansion of the platelet aggregation devices market.
The continuous increase in the new advancements and developments in the technology is growing the demand in the market with the rise in the market players in platelet aggregometer.
Because of a large patient population for target diseases such as arthritis, leukemia, and hemophilia, a strong presence of device manufacturers in the region, with the growing number of surgical procedures performed annually, is increasing the market growth.
The platelet aggregation devices are used to treat a variety of cardiovascular and bleeding conditions, as well as an increase in the growing awareness among healthcare professionals related to the benefits and uses of platelet aggregation devices; therefore North American platelet aggregation devices market is expected to grow at a remarkable pace.
Rising awareness among healthcare professionals about the benefits offered by platelet aggregation testing in disease diagnosis as well as the factors such as an increase in the number of surgical procedures performed in the United States, a large percentage of the population undergoing cardiovascular surgery, and an increase in the prevalence of orthopedic, bleeding, and urological disorders are all creating high growth opportunities for the industry players.
Increases in average device costs throughout the world are limiting market growth, as is a shortage of qualified persons and flaws in old aggregometry methods, affecting market growth and advancements of platelet aggregation devices.
This research report on the North America Platelet Aggregation Devices Market has been segmented and sub-segmented into the following categories
By End User:
Geographically, the North American market covers the largest share in the platelet aggregation devices market, and it is expected to grow more significantly during the forecast period. Regionally, the market's growth is attributed to the presence of device manufacturers, an increasing number of target disorders, and an increasing geriatric population. In addition, growing research and development costs in this region may elevate the market expansion.
The US platelet aggregation devices market is expected to show more significant growth in the platelet aggregation devices market. There is a high prevalence of chronic diseases like diabetes, cancer, etc., where diabetes is one of America's fastest-growing diseases, uplifting market growth. According to recent research, more than 100 million individuals in the United States have diabetes or pre-diabetes illness. Also, because hemophilia is a bleeding condition, and platelet aggregation testing has proven to be highly effective in sickness detection, there's been a rise in hemophilia disorder in the United States.
Similarly, Canada platelet aggregation devices market has an increasing prevalence of chronic diseases, more than 12.9 percent. It is due to the increase in the overweight, obesity with an aging population, and socioeconomic changes leading to a continuous rise in these frequent and expensive long-term health issues. Therefore, people are becoming increasingly sedentary as the middle class expands and as urbanization accelerates.
KEY MARKET PLAYERS
Key Market Players dominating the North America Platelet Aggregation Devices Market are Accriva Diagnostics, Helena Laboratories Corporation, BioData Corporation, Haemonetics Corporation, Siemens AG, Sysmex Corporation, Sentinel CH. S.p.A., Tem Group and Aggredyne, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org